Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
30 participants
OBSERVATIONAL
2006-07-31
2009-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
1. middle cerebral artery velocity time integral and resistive index using Doppler ultrasonography
2. cerebral oxygenation using near infrared spectroscopy (NIRS)
3. background neuronal electrical activity using an EEG. In addition, we will measure serial CSF concentration of neuroproteins, S100B, GFAP, NSE, TGF-ß, and IL-6, as evidence of ongoing neuronal damage and correlate the concentration with cerebral perfusion and activity as measured above.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Intraventricular Hemorrhage and Post Hemorrhagic Ventricular Dilation: Natural Course, Treatment, and Outcome
NCT00957840
Noninvasive Measurement of the Cerebral Autoregulation in Neonates and Infants With Complex Congenital Heart Disease
NCT04810013
Assessment of CSF Shunt Flow During Activities of Daily Living and Sleep With a Thermal Measurement Device
NCT07050628
Normal Pressure Hydrocephalus and Sleep Apnea
NCT04471740
Fetal Cerebrovascular Autoregulation in Congenital Heart Disease and Association With Neonatal Neurobehavior
NCT05767385
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
When hydrocephalus continues to be a problem despite removal of CSF, a ventricular-peritoneal (VP) shunt is placed. Approximately 50% of infants with hydrocephalus treated with removal of CSF resolve their hydrocephalus and do not require VP shunt placement. Placement of a VP shunt is difficult in extremely preterm infants due to increased risk of ulceration around the shunt site and the high protein concentration in CSF which can occlude the valve in the VP shunt requiring revision. Thus, hydrocephalus is usually treated with serial removal of CSF to allow for identification of those infant's whose hydrocephalus resolves over time. However, timing and method of CSF management is controversial because the effect of increasing hydrocephalus on cerebral perfusion, oxygenation, electrical activity, and neuronal damage has not been established.
Serial removal of CSF causes a change in intracranial volume/pressure that can be potentially transmitted to intracranial vessels. The caliber of cerebral vessels may be modified by this balance between intravascular and intracranial pressure, and if the caliber should change, the blood flow characteristics should also change. In cerebral veins and capillaries where intraluminal pressure is low, high intraventricular pressure may significantly affect blood flow and can cause venous stasis. NIRS measures cerebral oxygenation in capillaries and veins. Intracranial arteries and arterioles may be somewhat less affected, except when intraventricular pressure greatly increases. The resultant decrease in the arterial supply can affect tissue perfusion. Arterial flow can be measured by Doppler ultrasonography. Thus, there is concern that during periods of increasing or fluctuating ventricular size cerebral arterial perfusion may be compromised and further cerebral injury may result. Intracranial pressure is further influenced by the plasticity/deformability of the immature brain and the easy expansibility of the cranial vault due to the presence of sutures and open fontanelles.
There is indirect evidence from experiments in animals that ventricular distention itself may cause secondary brain injury. Thus, axonal stretching and disruption secondary to progressive ventriculomegaly is be associated with gliosis. Periventricular vascular distortion and compression may decrease cerebral blood flow causing ischemic injury to periventricular white matter. Inflammation and repair may interfere with CSF flow.
Little research is available that helps answer the primary question involved in clinical management of ventricular dilation in premature infants: Are there relationships between ventricular enlargement, cerebral perfusion, brain oxygen delivery, and on-going cerebral damage?
Doppler ultrasonography has been applied in premature infants to characterize post delivery changes in arterial and venous cerebral blood flow velocities.\[1\] Critically low superior vena cava flow measured by Doppler ultrasonography in the first 24 hours of life has been associated with intraventricular hemorrhage in premature infants born before 30 weeks gestation.\[2\] Using pulsed Doppler ultrasonography, the resistive index can be measured which is a inversely related to blood flow. In older infants with established hydrocephalus, cerebral blood flow resistive index appeared to be a good indicator of increased intracranial pressure.\[3\] However, in a review article, the value of Doppler indices alone in predicting increased intracranial pressure was strongly questioned.\[4\] In a recent article, the resistive index of the anterior cerebral artery decreased significantly after CSF drainage in infants with PHH. \[5\] Although Doppler ultrasonography is easy to perform, its role in detecting significant changes in cerebral perfusion associated with increased CSF volume and ventricular dilation is not yet established.
Near infrared spectroscopy (NIRS) is a portable non-invasive technique used to measure regional cerebral oxygen saturation in cerebral blood.\[6\] NIRS has been used to evaluate effect of head \[7\] and body position \[8\] on cerebral hemodynamics in preterm infants, and the effect of certain treatments, such as surfactant administration \[9\] and suctioning on conventional or high-frequency ventilation.\[10\] NIRS measurement of cerebral oxygenation and hemodynamics shows impairment in those neonates at risk for developing severe brain ischemia.\[11\] In premature infants with PHH, CSF fluid aspiration was associated with a significant increase in cerebral perfusion, cerebral blood volume, and oxidative metabolism.\[12,13\] In a small animal model of acute hydrocephalus, NIRS measurement of global cerebral blood flow using oxygen as a tracer was highly correlated to cerebral blood flow measured by radioactive microspheres over a wide range of increased intracranial pressure.\[14\] As intracranial pressure increased, NIRS measurement and absolute measurement of cerebral blood flow decreased. NIRS measured cerebral perfusion appears to directly reflect absolute cerebral blood flow and is sensitive enough to detect significant changes in cerebral perfusion which occur with evacuation of CSF in infants with PHH.
Amplitude-integrated EEG (aEEG) is a device used for neurologic surveillance. The cortical electrical activity is transformed into a single signal that represents overall electrocortical background activity of the brain. Specifically the upper and lower voltage margins and the amplitude of the tracing and the presence of seizure activity can be evaluated. In addition, the presence of sleep-wake cycles, a rhythmic sinusoidal variation in amplitude, can be evaluated. Infants \> 34 weeks gestation have predictable aEEG patterns. The signal depends on gestational age and postnatal age and standards for preterm infants have been reported.\[15,16\] In a case report, 2 preterm infants with PHH demonstrated abnormal sleep-wake cycles and markedly decreased cerebral electrical activity with increasing ventricular enlargement prior to clinical signs of increased intracranial pressure. In one infant, aEEG normalized after VP shunt placement.\[17\] To date, there are no clinical studies on the effect of aspiration of CSF on aEEG in preterm infants with PHH.
Biomarkers for cerebral injury have been used to predict severity of injury and long-term outcome, identify patients early at risk for poor neurologic outcomes, and evaluate effectiveness of therapeutic interventions. Neuronal specific enolase (NSE), a marker for neuronal damage, and S100B, secreted by astrocytes and a marker of glial/neuronal injury, have been shown to be increased in children after traumatic brain injury.\[18\] In preterm infants with PHH, S100B and glial fibrillary acid protein (GFAP), a structural protein in astrocytes, were significantly elevated in those infants who had brain parenchymal lesions and poor neurological outcomes.\[19\] These biomarkers are quickly metabolized and thus ongoing elevation would indicate ongoing damage. Transforming growth factor beta (TGF-ß), produced by fibroblasts and released into the CSF after injury, stimulates production of extracellular protein which could result in PHH due to a permanent obstruction to CSF flow.\[20\] Cytokine IL-6 is a marker of inflammation. There are no longitudinal studies on the effect of aspiration of CSF on these markers of cerebral damage in preterm infants with PHH.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
RETROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Utah
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
University of Utah Pediatrics / Neonatology
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Joanna Beachy, M.D.
Role: PRINCIPAL_INVESTIGATOR
University of Utah
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Utah
Salt Lake City, Utah, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
18833
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.